Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Galapagos   /   Galapagos september 2020

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,580   +0,040   (+0,16%) Dagrange 24,900 - 25,580 119.487   Gem. (3M) 87K

Galapagos september 2020

Volgen
6.207 Posts
Pagina: «« 1 ... 303 304 305 306 307 ... 311 »» | Laatste | Omlaag ↓
  2. [verwijderd] 30 september 2020 10:33
    quote:

    Anton8080 schreef op 30 september 2020 10:26:

    [...]

    Is nog behoudend, denk dat we gezien de lege pijplijn en forse uitgaven aan nutteloze onderzoeken snel richting 80 a 90 gaan......de bergtrein naar beneden is gaan rijden!

    (disclaimer: overmatig gebruik van sarcasme)
    haha inderdaad volledig onderbouwd met ijzersterke argumentatie ;)
  8. forum rang 7 Ron Kerstens 30 september 2020 10:44
    We hebben een werkwoord aan de man te danken (gemipperd worden= al je geld verliezen door een spike naar beneden) maar tot mijn ergernis duikt hij nu gewoon weer op en begint opnieuw het forum te vervuilen met zijn onzin. Wat is dat toch met forumleden waarvan de naam begint met een M ?
  16. forum rang 4 Wall Street Trader 30 september 2020 11:01
    Piet Wigerinck Galapagos NV - Chief Scientific Officer

    “We are excited by the rapid progress of GLPG3970 in the clinic,” said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos. “We now have multiple proof of concept studies running in parallel in several autoimmune diseases, and we aim to launch 2 additional Phase 2 studies, in Sjögren’s and systemic lupus erythematosus, early next year, further broadening the scope of the program. We have observed the dual mode of action of GLPG3970 in healthy volunteers, and through these patient trials, we aim to learn quickly whether clinical experience bears out the potential of our Toledo program to become a new paradigm in the treatment of inflammatory diseases.”

    GLPG3970 has immunomodulatory activity with a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines. GLPG3970 has shown encouraging preclinical activity in a number of inflammatory diseases, including inflammatory bowel diseases, rheumatoid arthritis, and psoriasis. Galapagos is executing on a broad program to discover and develop multiple series of compounds with different selectivity on Toledo targets, aimed at treating a broad range of autoimmune conditions with still important unmet medical need.

    CALOSOMA study: Phase 1 trial in psoriasis

    The Calosoma Phase 1 trial see:

    clinicaltrials.gov/ct2/show/NCT04106297

    is a double-blind, placebo-controlled study evaluating the safety, tolerability, PK and PD1 of GLPG3970 single and multiple ascending doses in up to 52 adult healthy male subjects. GLPG3970 will now be investigated for 6 weeks in 25 subjects with moderate to severe psoriasis. The first patient was dosed recently.

    SEA TURTLE study: Phase 2 trial in ulcerative colitis

    This Phase 2 trial is a double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, PK and PD of GLPG3970 in up to 30 subjects with moderately to severely active UC. GLPG3970 or a placebo will be administered orally once daily for 6 weeks, with the primary endpoint of change from baseline in total Mayo Clinical Score (MCS).

    LADYBUG study: Phase 2 trial in rheumatoid arthritis

    This Phase 2 trial is a double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, PK and PD of GLPG3970 in up to 25 participants with severely active RA and an inadequate response to methotrexate. GLPG3970 or a placebo will be administered orally once-daily for 6 weeks, with the primary endpoint of change from baseline of DAS28 CRP at week 6. Recruitment will take place in Europe.

    Gilead & TOLEDO: Gilead will have opt-in options developed by GLPG over the next 10 years.
    For each asset where GILD opts-in, GLPG will receive $150M and will be eligible to receive 20-24% tiered royalties on all future ex-European sales, with GLPG retaining full commercial rights in Europe.

    Each TOLEDO molecule will be considered a separate asset, with each having its own $150M opt-in fee. This could be an important source of future value!

    More than 50% of research at Galapagos is focused on TOLEDO and given Gilead's involvement and cost sharing, TOLEDO is fully funded. Importantly, if an opportunity called for a significant cash outlay, Gilead could come to the table.

    Note, management commentary suggests no nearto-intermediate term competition on the TOLEDO target for autoimmune diseases although, peers are investigating the target in oncology.

    Galapagos would have accepted a lower upfront payment if it excluded the TOLEDO program, which was a potential no-go on the part of Gilead since it may have prompted Galapagos to committing the best human and technical resources to the TOLEDO platform at Gilead's detriment.

    For more information regarding TOLEDO see PDF:

    www.iex.nl/Forum/Upload/2020/12576727...
6.207 Posts
Pagina: «« 1 ... 303 304 305 306 307 ... 311 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Galapagos meldt fraai succes rond nieuwe therapie: zit er weer muziek in het aandeel?

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. Galapagos: bemoedigende nieuwe resultaten met recidief/refractair non-Hodgkin lymfoom
  2. Kepler Cheuvreux zet Galapagos op verkooplijst
  3. Klinische resultaten Galapagos steunen celtherapie-hypothese
  4. Deutsche Bank verlaagt koersdoel Galapagos
  5. Financials en Shell doen goede zaken op terughoudend Damrak
  6. Galapagos herhaalt cash burn voor 2024
  7. Galapagos benoemt investeerder Nodelman in bestuur
  8. EcoR1 nog groter in Galapagos
  9. EcoR1 groter in Galapagos
  10. FMR LLC kleiner in Galapagos